Incretin actions and consequences of incretin-based therapies: Lessons from complementary animal models

Journal of Pathology

Volumn 238, Issue 2, 2016, Pages 345-358

  Renner, Simone ^a   Blutke, Andreas ^a   Streckel, Elisabeth ^a   Wanke, Rüdiger ^a   Wolf, Eckhard ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

GIP; GIP receptor; GLP1; GLP1 receptor; GLP1 receptor agonist; human; liraglutide; mouse; non human primate; pig

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE RECEPTOR; INCRETIN; ANTIDIABETIC AGENT; GASTRIC INHIBITORY POLYPEPTIDE; GASTRIC INHIBITORY POLYPEPTIDE RECEPTOR; HORMONE RECEPTOR; INSULIN; LIRAGLUTIDE;

HORMONE ACTION; MOUSE MODEL; NONHUMAN; PORCINE MODEL; PRIMATE MODEL; PRIORITY JOURNAL; REVIEW; TRANSGENIC PIG; ANIMAL; ANTAGONISTS AND INHIBITORS; DIABETES MELLITUS, TYPE 2; DISEASE MODEL; KNOCKOUT MOUSE; MOUSE; PANCREAS ISLET BETA CELL; PHYSIOLOGY; PIG; PRIMATE; RODENT; SECRETION (PROCESS); TRANSGENIC ANIMAL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN; INSULIN-SECRETING CELLS; LIRAGLUTIDE; MICE; MICE, KNOCKOUT; PRIMATES; RECEPTORS, GASTROINTESTINAL HORMONE; RODENTIA; SWINE;

EID: 84951310148     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4655     Document Type: Review

References (150)

1. Elrick H, Stimmler L, Hlad CJ Jr, et al., Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964; 24: 1076-1082.
2. McIntyre N, Holdsworth CD, Turner DS,. New interpretation of oral glucose tolerance. Lancet 1964; 2: 20-21.
3. Brown JC, Mutt V, Pederson RA,. Further purification of a polypeptide demonstrating enterogastrone activity. J Physiol 1970; 209: 57-64.
4. Schmidt WE, Siegel EG, Creutzfeldt W,. Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia 1985; 28: 704-707.
5. Miyawaki K, Yamada Y, Yano H, et al., Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci USA 1999; 96: 14843-14847.
6. Scrocchi LA, Brown TJ, MaClusky N, et al., Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 1996; 2: 1254-1258.
7. Preitner F, Ibberson M, Franklin I, et al., Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors. J Clin Invest 2004; 113: 635-645.
8. Herbach N, Goeke B, Schneider M, et al., Overexpression of a dominant negative GIP receptor in transgenic mice results in disturbed postnatal pancreatic islet and β cell development. Regul Pept 2005; 125: 103-117.
9. Renner S, Fehlings C, Herbach N, et al., Glucose intolerance and reduced proliferation of pancreatic β cells in transgenic pigs with impaired glucose-dependent insulinotropic polypeptide function. Diabetes 2010; 59: 1228-1238.
10. Campbell JE, Drucker DJ,. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 2013; 17: 819-837.
11. Dolensek J, Rupnik MS, Stozer A,. Structural similarities and differences between the human and the mouse pancreas. Islets 2015; 7: e1024405.
12. Aigner B, Renner S, Kessler B, et al., Transgenic pigs as models for translational biomedical research. J Mol Med (Berl) 2010; 88: 653-664.
13. Larsen MO, Rolin B,. Use of the Gottingen minipig as a model of diabetes, with special focus on type 1 diabetes research. ILAR J 2004; 45: 303-313.
14. Cataland S, Crockett SE, Brown JC, et al., Gastric inhibitory polypeptide (GIP) stimulation by oral glucose in man. J Clin Endocrinol Metab 1974; 39: 223-228.
15. Elliott RM, Morgan LM, Tredger JA, et al., Glucagon-like peptide-1 (7-36) amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24 h secretion patterns. J Endocrinol 1993; 138: 159-166.
16. Lindgren O, Carr RD, Deacon CF, et al., Incretin hormone and insulin responses to oral versus intravenous lipid administration in humans. J Clin Endocrinol Metab 2011; 96: 2519-2524.
17. Lindgren O, Pacini G, Tura A, et al., Incretin effect after oral amino acid ingestion in humans. J Clin Endocrinol Metab 2015; 100: 1172-1176.
18. Gagnon J, Baggio LL, Drucker DJ, et al., Ghrelin is a novel regulator of GLP-1 secretion. Diabetes 2015; 64: 1513-1521.
19. Orskov C, Wettergren A, Holst JJ,. Biological effects and metabolic rates of glucagon-like peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes 1993; 42: 658-661.
20. Furness JB, Rivera LR, Cho HJ, et al., The gut as a sensory organ. Nat Rev Gastroenterol Hepatol 2013; 10: 729-740.
21. Wheeler MB, Gelling RW, McIntosh CH, et al., Functional expression of the rat pancreatic islet glucose-dependent insulinotropic polypeptide receptor: ligand binding and intracellular signaling properties. Endocrinology 1995; 136: 4629-4639.
22. Drucker DJ,. Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls. Diabetes 2013; 62: 3316-3323.
23. Pyke C, Heller RS, Kirk RK, et al., GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 2014; 155: 1280-1290.
24. Richards P, Parker HE, Adriaenssens AE, et al., Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model. Diabetes 2014; 63: 1224-1233.
25. Seino Y, Fukushima M, Yabe D,. GIP and GLP-1, the two incretin hormones: similarities and differences. J Diabetes Invest 2010; 1: 8-23.
26. Nauck MA, Bartels E, Orskov C, et al., Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 1993; 76: 912-917.
27. Vilsboll T, Krarup T, Madsbad S, et al., Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept 2003; 114: 115-121.
28. Christensen M, Calanna S, Sparre-Ulrich AH, et al., Glucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes. Diabetes 2015; 64: 72-78.
29. Meier JJ, Nauck MA, Kranz D, et al., Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 2004; 53: 654-662.
30. Vilsboll T, Agerso H, Lauritsen T, et al., The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects. Regul Pept 2006; 137: 168-172.
31. Vollmer K, Holst JJ, Baller B, et al., Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 2008; 57: 678-687.
32. Donath MY, Burcelin R,. GLP-1 effects on islets: hormonal, neuronal, or paracrine? Diabetes Care 2013; 36 (suppl 2): S145-148.
33. Nauck MA, Heimesaat MM, Orskov C, et al., Preserved incretin activity of glucagon-like peptide 1 (7-36 amide) but not of synthetic human gastric inhibitory polypeptide in patients with type 2 diabetes mellitus. J Clin Invest 1993; 91: 301-307.
34. Lynn FC, Pamir N, Ng EH, et al., Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. Diabetes 2001; 50: 1004-1011.
35. Piteau S, Olver A, Kim SJ, et al., Reversal of islet GIP receptor down-regulation and resistance to GIP by reducing hyperglycemia in the Zucker rat. Biochem Biophys Res Commun 2007; 362: 1007-1012.
36. Harada N, Yamada Y, Tsukiyama K, et al., A novel GIP receptor splice variant influences GIP sensitivity of pancreatic β cells in obese mice. Am J Physiol Endocrinol Metab 2008; 294: E61-68.
37. Zhou J, Livak MF, Bernier M, et al., Ubiquitination is involved in glucose-mediated downregulation of GIP receptors in islets. Am J Physiol Endocrinol Metab 2007; 293: E538-547.
38. Saxena R, Hivert MF, Langenberg C, et al., Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet 2010; 42: 142-148.
39. Nauck MA, Baller B, Meier JJ,. Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes. Diabetes 2004; 53 (suppl 3): S190-196.
40. Xu G, Kaneto H, Laybutt DR, et al., Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes. Diabetes 2007; 56: 1551-1558.
41. Hojberg PV, Vilsboll T, Rabol R, et al., Four weeks of near-normalization of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 2009; 52: 199-207.
42. Meier JJ, Nauck MA,. Is the diminished incretin effect in type 2 diabetes just an epiphenomenon of impaired β cell function? Diabetes 2010; 59: 1117-1125.
43. Meier JJ, Nauck MA,. Incretin-based therapies: where will we be 50 years from now? Diabetologia 2015; 58: 1745-1750.
44. Widenmaier SB, Ao Z, Kim SJ, et al., Suppression of p38 MAPK and JNK via Akt-mediated inhibition of apoptosis signal-regulating kinase 1 constitutes a core component of the β cell pro-survival effects of glucose-dependent insulinotropic polypeptide. J Biol Chem 2009; 284: 30372-30382.
45. Ehses JA, Casilla VR, Doty T, et al., Glucose-dependent insulinotropic polypeptide promotes β(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase. Endocrinology 2003; 144: 4433-4445.
46. Kim SJ, Nian C, Widenmaier S, et al., Glucose-dependent insulinotropic polypeptide-mediated up-regulation of β cell antiapoptotic Bcl-2 gene expression is coordinated by cyclic AMP (cAMP) response element binding protein (CREB) and cAMP-responsive CREB coactivator 2. Mol Cell Biol 2008; 28: 1644-1656.
47. Kim SJ, Winter K, Nian C, et al., Glucose-dependent insulinotropic polypeptide (GIP) stimulation of pancreatic β cell survival is dependent upon phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1, and down-regulation of bax expression. J Biol Chem 2005; 280: 22297-22307.
48. Trumper A, Trumper K, Horsch D,. Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in β(INS-1) cells. J Endocrinol 2002; 174: 233-246.
49. Widenmaier SB, Sampaio AV, Underhill TM, et al., Non-canonical activation of Akt/protein kinase B in β cells by the incretin hormone glucose-dependent insulinotropic polypeptide. J Biol Chem 2009; 284: 10764-10773.
50. Yabe D, Seino Y,. Incretin actions beyond the pancreas: lessons from knockout mice. Curr Opin Pharmacol 2013; 13: 946-953.
51. Hansotia T, Maida A, Flock G, et al., Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. J Clin Invest 2007; 117: 143-152.
52. Pamir N, Lynn FC, Buchan AM, et al., Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis. Am J Physiol Endocrinol Metab 2003; 284: E931-939.
53. Hansotia T, Baggio LL, Delmeire D, et al., Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes 2004; 53: 1326-1335.
54. Maida A, Hansotia T, Longuet C, et al., Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for β cell survival in mice. Gastroenterology 2009; 137: 2146-2157.
55. Miyawaki K, Yamada Y, Ban N, et al., Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 2002; 8: 738-742.
56. Ugleholdt R, Pedersen J, Bassi MR, et al., Transgenic rescue of adipocyte glucose-dependent insulinotropic polypeptide receptor expression restores high fat diet-induced body weight gain. J Biol Chem 2011; 286: 44632-44645.
57. Suzuki K, Harada N, Yamane S, et al., Transcriptional regulatory factor X6 (Rfx6) increases gastric inhibitory polypeptide (GIP) expression in enteroendocrine K-cells and is involved in GIP hypersecretion in high fat diet-induced obesity. J Biol Chem 2013; 288: 1929-1938.
58. Nasteska D, Harada N, Suzuki K, et al., Chronic reduction of GIP secretion alleviates obesity and insulin resistance under high-fat diet conditions. Diabetes 2014; 63: 2332-2343.
59. Kim SJ, Nian C, Karunakaran S, et al., GIP-overexpressing mice demonstrate reduced diet-induced obesity and steatosis, and improved glucose homeostasis. PLoS One 2012; 7: e40156.
60. -/- mice. Diabetes 1998; 47: 1046-1052.
61. Finan B, Yang B, Ottaway N, et al., Targeted estrogen delivery reverses the metabolic syndrome. Nat Med 2012; 18: 1847-1856.
62. Sisley S, Gutierrez-Aguilar R, Scott M, et al., Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect. J Clin Invest 2014; 124: 2456-2463.
63. Ussher JR, Baggio LL, Campbell JE, et al., Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection. Mol Metab 2014; 3: 507-517.
64. Smith EP, An Z, Wagner C, et al., The role of β cell glucagon-like peptide-1 signaling in glucose regulation and response to diabetes drugs. Cell Metab 2014; 19: 1050-1057.
65. Lamont BJ, Li Y, Kwan E, et al., Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice. J Clin Invest 2012; 122: 388-402.
66. Magnuson MA, Osipovich AB,. Pancreas-specific Cre driver lines and considerations for their prudent use. Cell Metab 2013; 18: 9-20.
67. Song J, Xu Y, Hu X, et al., Brain expression of Cre recombinase driven by pancreas-specific promoters. Genesis 2010; 48: 628-634.
68. Volz-Peters A, Peters H, Berghöfer P, et al., Expression of a dominant-negative GIP receptor induces diabetes mellitus in transgenic mice [Abstract]. Exp Clin Endocrinol Diabetes 2000; 108 (Suppl 1): 40.
69. Herbach N, Goke B, Wolf E, et al., Diets influence the diabetic phenotype of transgenic mice expressing a dominant negative glucose-dependent insulinotropic polypeptide receptor (GIPRdn). Regul Pept 2008; 146: 260-270.
70. Herbach N, Bergmayr M, Goke B, et al., Postnatal development of numbers and mean sizes of pancreatic islets and β cells in healthy mice and GIPRdn transgenic diabetic mice. PLoS One 2011; 6: e22814.
71. Herbach N, Schairer I, Blutke A, et al., Diabetic kidney lesions of GIPRdn transgenic mice: podocyte hypertrophy and thickening of the GBM precede glomerular hypertrophy and glomerulosclerosis. Am J Physiol Renal Physiol 2009; 296: F819-829.
72. Blutke A, Block C, Berendt F, et al., Differential glomerular proteome analysis of two murine nephropathy models at onset of albuminuria. Proteom Clin Appl 2011; 5: 375-381.
73. dn transgenic diabetic mice Doctoral Thesis, LMU Munich; 2014.
74. Tabak AG, Jokela M, Akbaraly TN, et al., Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 2009; 373: 2215-2221.
75. Renner S, Romisch-Margl W, Prehn C, et al., Changing metabolic signatures of amino acids and lipids during the prediabetic period in a pig model with impaired incretin function and reduced β cell mass. Diabetes 2012; 61: 2166-2175.
76. Wang TJ, Larson MG, Vasan RS, et al., Metabolite profiles and the risk of developing diabetes. Nat Med 2011; 17: 448-453.
77. Li Z, Zhang H, Liu J, et al., Reducing plasma membrane sphingomyelin increases insulin sensitivity. Mol Cell Biol 2011; 31: 4205-4218.
78. Yano M, Watanabe K, Yamamoto T, et al., Mitochondrial dysfunction and increased reactive oxygen species impair insulin secretion in sphingomyelin synthase 1-null mice. J Biol Chem 2011; 286: 3992-4002.
79. Larsen MO, Rolin B, Wilken M, et al., Parameters of glucose and lipid metabolism in the male Gottingen minipig: influence of age, body weight, and breeding family. Comp Med 2001; 51: 436-442.
80. Tibaldi JM,. Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes. Adv Ther 2014; 31: 289-317.
81. Rolin B, Larsen MO, Gotfredsen CF, et al., The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases β cell mass in diabetic mice. Am J Physiol Endocrinol Metab 2002; 283: E745-752.
82. Sturis J, Gotfredsen CF, Romer J, et al., GLP-1 derivative liraglutide in rats with β cell deficiencies: influence of metabolic state on β cell mass dynamics. Br J Pharmacol 2003; 140: 123-132.
83. Raun K, von Voss P, Gotfredsen CF, et al., Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes 2007; 56: 8-15.
84. Larsen PJ, Fledelius C, Knudsen LB, et al., Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes 2001; 50: 2530-2539.
85. Ribel U, Larsen MO, Rolin B, et al., NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs. Eur J Pharmacol 2002; 451: 217-225.
86. Blonde L, Russell-Jones D,. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies. Diabetes Obes Metab 2009; 11 (suppl 3): 26-34.
87. Buse JB, Rosenstock J, Sesti G, et al., Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week, randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374: 39-47.
88. Meier JJ,. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012; 8: 728-742.
89. European Medicines Agency. Assessment report for Victoza, Doc. Ref. EMEA/379172/2009: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment-report/human/001026/WC500050016.pdf 2009 [accessed 4 November 2015].
90. Vilsboll T, Zdravkovic M, Le-Thi T, et al., Liraglutide, a long-acting human glucagon-like peptide-1 analog given as monotherapy, significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007; 30: 1608-1610.
91. de Heer J, Holst JJ,. Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1. Diabetes 2007; 56: 438-443.
92. Buse JB, Henry RR, Han J, et al., Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2628-2635.
93. Tamura K, Minami K, Kudo M, et al., Liraglutide improves pancreatic β cell mass and function in alloxan-induced diabetic mice. PLoS One 2015; 10: e0126003.
94. Shimoda M, Kanda Y, Hamamoto S, et al., The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic β cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes. Diabetologia 2011; 54: 1098-1108.
95. Larsen PJ, Wulff EM, Gotfredsen CF, et al., Combination of the insulin sensitizer, pioglitazone, and the long-acting GLP-1 human analog, liraglutide, exerts potent synergistic glucose-lowering efficacy in severely diabetic ZDF rats. Diabetes Obes Metab 2008; 10: 301-311.
96. Kimura T, Kaneto H, Shimoda M, et al., Protective effects of pioglitazone and/or liraglutide on pancreatic β cells in db/db mice: comparison of their effects between in an early and advanced stage of diabetes. Mol Cell Endocrinol 2015; 400: 78-89.
97. Vrang N, Jelsing J, Simonsen L, et al., The effects of 13 weeks of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis. Am J Physiol Endocrinol Metab 2012; 303: E253-264.
98. Buteau J, Roduit R, Susini S, et al., Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in β(INS-1) cells. Diabetologia 1999; 42: 856-864.
99. Bock T, Pakkenberg B, Buschard K,. The endocrine pancreas in non-diabetic rats after short-term and long-term treatment with the long-acting GLP-1 derivative NN2211. Acta Pathol Microbiol Immunol Scand 2003; 111: 1117-1124.
100. Ellenbroek JH, Tons HA, Westerouen van Meeteren MJ, et al., Glucagon-like peptide-1 receptor agonist treatment reduces β cell mass in normoglycaemic mice. Diabetologia 2013; 56: 1980-1986.
101. Montanya E, Nacher V, Biarnes M, et al., Linear correlation between β cell mass and body weight throughout the lifespan in Lewis rats: role of β cell hyperplasia and hypertrophy. Diabetes 2000; 49: 1341-1346.
102. Svenstrup K, Skau M, Pakkenberg B, et al., Postnatal development of β cells in rats. Proposed explanatory model. APMIS 2002; 110: 372-378.
103. Bregenholt S, Moldrup A, Blume N, et al., The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits β cell apoptosis in vitro. Biochem Biophys Res Commun 2005; 330: 577-584.
104. Friedrichsen BN, Neubauer N, Lee YC, et al., Stimulation of pancreatic β cell replication by incretins involves transcriptional induction of cyclin D1 via multiple signalling pathways. J Endocrinol 2006; 188: 481-492.
105. Merani S, Truong W, Emamaullee JA, et al., Liraglutide, a long-acting human glucagon-like peptide 1 analog, improves glucose homeostasis in marginal mass islet transplantation in mice. Endocrinology 2008; 149: 4322-4328.
106. Emamaullee JA, Merani S, Toso C, et al., Porcine marginal mass islet autografts resist metabolic failure over time and are enhanced by early treatment with liraglutide. Endocrinology 2009; 150: 2145-2152.
107. Gotfredsen CF, Molck AM, Thorup I, et al., The human GLP-1 analogs liraglutide and semaglutide: absence of histopathological effects on the pancreas in nonhuman primates. Diabetes 2014; 63: 2486-2497.
108. Nyborg NC, Molck AM, Madsen LW, et al., The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species. Diabetes 2012; 61: 1243-1249.
109. Butler AE, Janson J, Soeller WC, et al., Increased β cell apoptosis prevents adaptive increase in β cell mass in mouse model of type 2 diabetes: evidence for role of islet amyloid formation rather than direct action of amyloid. Diabetes 2003; 52: 2304-2314.
110. Saisho Y, Butler AE, Manesso E, et al., β cell mass and turnover in humans: effects of obesity and aging. Diabetes Care 2013; 36: 111-117.
111. Gier B, Matveyenko AV, Kirakossian D, et al., Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras (G12D) mouse model. Diabetes 2012; 61: 1250-1262.
112. Nachnani JS, Bulchandani DG, Nookala A, et al., Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia 2010; 53: 153-159.
113. Ahmad SR, Swann J., Exenatide and rare adverse events. N Engl J Med 2008; 358: 1970-1971; discussion, 1971-1972.
114. Lowenfels AB, Maisonneuve P, Cavallini G, et al., Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med 1993; 328: 1433-1437.
115. Yang L, He Z, Tang X, et al., Type 2 diabetes mellitus and the risk of acute pancreatitis: a meta-analysis. Eur J Gastroenterol Hepatol 2013; 25: 225-231.
116. Tatarkiewicz K, Smith PA, Sablan EJ, et al., Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents. Am J Physiol Endocrinol Metab 2010; 299: E1076-1086.
117. Jensen TM, Saha K, Steinberg WM,. Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care 2015; 38: 1058-1066.
118. Butler AE, Campbell-Thompson M, Gurlo T, et al., Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013; 62: 2595-2604.
119. Kahn SE,. Incretin therapy and islet pathology: a time for caution. Diabetes 2013; 62: 2178-2180.
120. Yachida S, Jones S, Bozic I, et al., Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010; 467: 1114-1117.
121. Koehler JA, Baggio LL, Lamont BJ, et al., Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice. Diabetes 2009; 58: 2148-2161.
122. Koehler JA, Baggio LL, Cao X, et al., Glucagon-like peptide-1 receptor agonists increase pancreatic mass by induction of protein synthesis. Diabetes 2015; 64: 1046-1056.
123. Tamborlane WV, Klingensmith G,. Crisis in care: limited treatment options for type 2 diabetes in adolescents and youth. Diabetes Care 2013; 36: 1777-1778.
124. Klein DJ, Battelino T, Chatterjee DJ, et al., Liraglutide's safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes Technol Ther 2014; 16: 679-687.
125. Streckel E, Braun-Reichhart C, Herbach N, et al., Effects of the glucagon-like peptide-1 receptor agonist liraglutide in juvenile transgenic pigs modeling a pre-diabetic condition. J Transl Med 2015; 13: 73.
126. Jelsing J, Vrang N, Hansen G, et al., Liraglutide: short-lived effect on gastric emptying-long-lasting effects on body weight. Diabetes Obes Metab 2012; 14: 531-538.
127. Nauck MA, Kemmeries G, Holst JJ, et al., Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes 2011; 60: 1561-1565.
128. Iepsen EW, Torekov SS, Holst JJ,. Liraglutide for type 2 diabetes and obesity: a 2015 update. Expert Rev Cardiovasc Ther 2015; 13: 753-767.
129. Renner S, Braun-Reichhart C, Blutke A, et al., Permanent neonatal diabetes in INS(C94Y) transgenic pigs. Diabetes 2013; 62: 1505-1511.
130. Micale SJ, Kane MP, Hogan E,. Off-label use of liraglutide in the management of a pediatric patient with type 2 diabetes mellitus. Case Rep Pediatr 2013; 2013: 703925.
131. Kieffer TJ, Habener JF,. The glucagon-like peptides. Endocr Rev 1999; 20: 876-913.
132. Abbott A., Inside the first pig biobank. Nature 2015; 519: 397-398.
133. Escareno CE, Azagury DE, Flint RS, et al., Establishing a reproducible large animal survival model of laparoscopic Roux-en-Y gastric bypass. Surg Obes Relat Dis 2012; 8: 764-769.
134. Lindqvist A, Spegel P, Ekelund M, et al., Gastric bypass improves β cell function and increases β cell mass in a porcine model. Diabetes 2014; 63: 1665-1671.
135. Li S, Flisikowska T, Kurome M, et al., Dual fluorescent reporter pig for Cre recombination: transgene placement at the ROSA26 locus. PLoS One 2014; 9: e102455.
136. Luo W, Li Z, Li P, et al., Expression of Cre recombinase in alveolar epithelial cells of the AQP2-Cre transgenic mini-pigs. Cell Physiol Biochem 2014; 34: 1597-1613.
137. Klymiuk N, Bocker W, Schonitzer V, et al., First inducible transgene expression in porcine large animal models. FASEB J 2012; 26: 1086-1099.
138. Klymiuk N, Seeliger F, Bohlooly-Y M, et al., Tailored pig models for preclinical efficacy and safety testing of targeted therapies. Toxicol Pathol; pii: 0192623315609688.
139. Kobilka BK,. G protein coupled receptor structure and activation. Biochim Biophys Acta 2007; 1768: 794-807.
140. Volz A., Klonierung und funktionelle Charakterisierung des humanen GIP-Rezeptors. Doctoral Thesis, Philipps-Universität Marburg, Tectum Wissenschaftsverlag Marburg; 1997.
141. Streckel E., Effects of the long-acting glucagon-like peptide-1 receptor agonist liraglutide in adolescent pigs with impaired glucose-dependent insulinotropic polypeptide receptor function. Doctoral Thesis, LMU Munich; 2013.
142. Li X, Jiang L, Yang M, et al., Expression of CTRP3, a novel adipokine, in rats at different pathogenic stages of type 2 diabetes mellitus and the impacts of GLP-1 receptor agonist on it. J Diabetes Res 2014; 2014: 398518.
143. Chen S, Okahara F, Osaki N, et al., Increased GIP signaling induces adipose inflammation via a HIF-1α-dependent pathway and impairs insulin sensitivity in mice. Am J Physiol Endocrinol Metab 2015; 308: E414-425.
144. Gogebakan O, Osterhoff MA, Schuler R, et al., GIP increases adipose tissue expression and blood levels of MCP-1 in humans and links high energy diets to inflammation: a randomised trial. Diabetologia 2015; 58: 1759-1768.
145. Varol C, Zvibel I, Spektor L, et al., Long-acting glucose-dependent insulinotropic polypeptide ameliorates obesity-induced adipose tissue inflammation. J Immunol 2014; 193: 4002-4009.
146. Lee YS, Park MS, Choung JS, et al., Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes. Diabetologia 2012; 55: 2456-2468.
147. Irwin N, Francis JM, Flatt PR,. Alterations of glucose-dependent insulinotropic polypeptide (GIP) during cold acclimation. Regul Pept 2011; 167: 91-96.
148. Iepsen EW, Lundgren JR, Hartmann B, et al., GLP-1 receptor agonist treatment increases bone formation and prevents bone loss in weight-reduced obese women. J Clin Endocrinol Metab 2015; 100: 2909-2917.
149. Ussher JR, Drucker DJ,. Cardiovascular actions of incretin-based therapies. Circ Res 2014; 114: 1788-1803.
150. Koska J, Sands M, Burciu C, et al., Exenatide protects against glucose- and lipid-induced endothelial dysfunction: evidence for direct vasodilation effect of GLP-1 receptor agonists in humans. Diabetes 2015; 64: 2624-2635.